Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 12/11/2019
SIETES contiene 92833 citas

 
 
 1 a 20 de 49 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Davies SJC, Jackson PR, Ramsay L E, Ghahramani P. Drug intolerance due to nonspecific adverse effects related to psychiatric morbidity in hypertensive patients. Arch Intern Med 2003;163:592-600. [Ref.ID 65458]
2. Cita con resumen
Sanmuganathan PS, Ghahramani P, Jackson PR, Wallis EJ, Ramsay L E. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 2001;85:265-71. [Ref.ID 59673]
3. Cita con resumen
Jackson PR, Wallis EJ, Haq IU, Ramsay L E. Statins for primary prevention: at what coronary risk is safety assured?. Br J Clin Pharmacol 2001;52:439-46. [Ref.ID 58974]
4.
Jackson PR, Wallis EJ, Ramsay L E. Prevention of stroke and transient ischaemic attack. Lancet 2001;358:762. [Ref.ID 58359]
5.Tiene citas relacionadas
Ramsay L E, Sanmuganathan PS, Wallis EJ, Jackson PR. Aspirin for primary prevention. Treatment policy should be based on all trial evidence, not subgroup analysis. BMJ 2000;321:1472. [Ref.ID 54323]
6.Tiene citas relacionadas
Jackson PR, Wallis EJ, Ramsay L E. Optimal age for starting lipid lowering treatment. Adjusted data do not justify a lower optimal age. BMJ 2000;321:637-8. [Ref.ID 52705]
7.Tiene citas relacionadas
Ramsay L E, Williams B, Potter J F, Johnston GD, MacGregor GA, Poston L, Poulter N R, Russell G. Management of hypertension. Authors' reply (Ramsay et al). BMJ 2000;320:579-80. [Ref.ID 49634]
8.Tiene citas relacionadas
Ramsay L E, Williams B, Johnston GD, MacGregor GA, Poston L, Potter J F, Poulter N R, Russell G. British Hypertension Society guidelines for hypertension management 1999: summary. BMJ 1999;319:630-5. [Ref.ID 46266]
9.Tiene citas relacionadas
Ramsay L E, Wallis EJ, Haq IU, Jackson PR, Yeo WW. Cholesterol screening and management guidelines. Policy based on Sheffield table fully satisfies authors' criteria. BMJ 1999;318:1140-1. [Ref.ID 44435]
10.Tiene citas relacionadas
Ramsay L E, Wallis EJ, Haq IU, Jackson PR. Coronary risk assessment methods and cholesterol lowering. Lancet 1999;353:1095. [Ref.ID 43584]
11.Tiene citas relacionadas
Ramsay L E, Wallis EJ, Haq IU, Yeo WW, Jackson PR. Drug therapy for coronary heart disease: the Sheffield table. Lancet 1998;351:443. [Ref.ID 42648]
12.Tiene citas relacionadas
Wallis EJ, Ramsay L E, Yeo WW, Jackson PR. Statins for prevention of stroke. Lancet 1998;352:909-10. [Ref.ID 40514]
13.Tiene citas relacionadas
Ramsay L E, Wallis EJ, Haq IU, Yeo WW, Jackson PR. Use of statins. Sheffield table is useful. BMJ 1998;317:473-4. [Ref.ID 40335]
14.
Ghahramani P, Rowland-Yeo K, Yeo WW, Jackson PR, Ramsay L E. Proteing binding of aspirin and salicylate measured by in vivo ultrafiltration. Clin Pharmacol Ther 1998;63:285-95. [Ref.ID 38292]
15.
Wallis EJ, Ramsay L E, Jackson PR, Yeo WW, Williamson R. Drug therapy for coronary heart disease: the Sheffield table. Lancet 1997;350:1852. [Ref.ID 36533]
16.
Wallis EJ, Ramsay L E, Yeo WW, Jackson PR, Pickin M, Haq IU. Use of statins. Evidence on effectiveness is stronger for statins than for other treatments. BMJ 1997;315:1618-9. [Ref.ID 36016]
17.Tiene citas relacionadas
Waller PC, Ramsay L E. Magnesium infusion in acute myocardial infarction. Lancet 1986;1:551. [Ref.ID 33384]
18.Tiene citas relacionadas
Ramsay L E. Commentary: placebo run ins have some value. BMJ 1997;314:1193. [Ref.ID 32367]
19.
Ghahramani P, Ellis SW, Lennard MS, Ramsay L E, Tucker GT. Cytochromes P450 mediating the N-demethylation of amitriptyline. Br J Clin Pharmacol 1997;43:137-44. [Ref.ID 31035]
20.
Ramsay L E, Haq IU, Jackson PR, Yeo WW. Sheffield risk and treatment table for primary prevention of coronary heart disease. Lancet 1996;348:1040-1. [Ref.ID 29556]
Seleccionar todas
 
 1 a 20 de 49 siguiente >>